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OBJECTIVES: To assess and analyze the number, type, and extent of risk-sharing 
agreements worldwide based on published literature. 
METHODS: A structured literature 
review using predefi ned search criteria was conducted to identify references to, 
or descriptions of, health outcome-based risk-sharing agreements within peer-reviewed 
and trade publications between the years of 2000–2010. The identifi ed publications 
were categorized by strength of evidence (i.e., systematic or non-systematic), and then 
aggregated by type of agreement, technology, and companies involved within the 
agreement. Analysis was completed to demonstrate commonalities among identifi ed 
agreements as well as their unique aspects. 
 RESULTS: Five database and publication 
sources were reviewed using 17 predefi ned search terms. The literature review suggests 
that many risk-sharing agreements are not published and those that are vary widely 
in design, scope, and intent. The search resulted in 61 abstracts which identifi ed eight 
individual published risk-sharing schemes. While all identifi ed agreements link 
improvements in health outcomes with reimbursement, defi nitions of what constitutes 
improved health outcomes, as well as the type of evidence required to prove that 
improvement, varied dramatically. The published risk-sharing schemes were from the 
UK (n 3), United States (n 3), France (n 1), and Sweden (n 1). There is more 
publically available information on agreements outside of the United States, but it is 
unclear the extent to which this is due to greater transparency in reimbursement versus 
a refl ection of more risk-sharing agreements. 
CONCLUSIONS: Health outcomesbased 
risk-sharing agreements offer the potential for both benefi t and frustration to 
manufacturers and payers alike. The ability to review progress within this fi eld to-date 
and attempt to offer trends toward best practices will be key to the long-term viability 
of these novel reimbursement efforts. Despite the heterogeneity of agreement types, 
methods, and foci, successful utilization of these agreements has been achieved and 
could potentially offer a guide for replication in future use. 
